1. Homepage
  2. Equities
  3. Hong Kong
  4. Hong Kong Stock Exchange
  5. RemeGen Co., Ltd.
  6. News
  7. All News
    9995   CNE1000048G6

REMEGEN CO., LTD.

(9995)
  Report
Delayed Hong Kong Stock Exchange  -  04:08 2022-06-30 am EDT
43.95 HKD   +5.90%
05/05RemeGen Co., Ltd. Approves Appointment of Chen Yunjin as Independent Non-Executive Director
CI
04/28RemeGen Widens Q1 Loss as R&D, Selling Expenses Balloon
MT
04/27RemeGen Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022
CI
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies
All news about REMEGEN CO., LTD.
05/05RemeGen Co., Ltd. Approves Appointment of Chen Yunjin as Independent Non-Executive Dire..
CI
04/28RemeGen Widens Q1 Loss as R&D, Selling Expenses Balloon
MT
04/27RemeGen Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022
CI
04/12RemeGen Co., Ltd. Announces Executive Changes
CI
04/11UBS Upgrades RemeGen to Buy From Neutral, Adjusts Price Target to HK$75.03 From HK$108
MT
03/31RemeGen Lists in Shanghai's STAR Market
MT
03/22RemeGen Prices Shanghai IPO to Raise $410 Million
MT
02/20RemeGen Turns to Profit in 2021 on Launch of Core Autoimmune, Cancer Drugs; Shares Rise..
MT
02/20RemeGen Co., Ltd. Reports Earnings Results for the Fourth Quarter Ended December 31, 20..
CI
01/25Remegen's Telitacicept Demonstrates Positive Results in Phase II Trial in Treatment of ..
CI
01/24RemeGen Completes Phase 2 Trial of Sjögren's Syndrome Treatment in China
MT
01/24RemeGen Co., Ltd. Completes the Phase II Clinical Study for Telitacicept to Treat Patie..
CI
01/12Hong Kong Stocks Jump to Seven-Week High; RemeGen Climbs 9% on Shanghai IPO Approval
MT
01/12Chinese Regulator Approves RemeGen's Shanghai IPO Application; Shares Jump 9%
MT
01/05Chinese Regulators Grant Conditional Marketing Approval to Remegen's Urothelial Carcino..
MT
01/05RemeGen Co., Ltd. Announces National Medical Products Administration Grants Conditional..
CI
2021RemeGen's Trustee Acquires Shares Under Share Award, Trust Scheme
MT
2021RemeGen Buying Filtration Devices From Contract Development Firm
MT
2021Chinese Regulators Accept RemeGen's Application for Clinical Trial of Combination Drugs..
MT
2021China Includes Two RemeGen Drugs to New National Reimbursement List
MT
2021RemeGen Shareholders to Vote Dec. 20 on Employee Incentive Tied to Shanghai IPO
MT
2021RemeGen's Telitacicept and Disitamab Vedotin Enter China's National Reimbursement Drug ..
CI
2021RemeGen's January-September Loss Widens on Higher Expenses
MT
2021RemeGen Gets STAR Market Listing Approval a Year after Hong Kong Debut
MT
2021Certain Domestic Shares of RemeGen Co., Ltd. are subject to a Lock-Up Agreement Ending ..
CI
2021RemeGen Files for Shanghai IPO One Year after Hong Kong Debut
MT
2021RemeGen Co., Ltd. Provides Earnings Guidance for the Period from January to September 2..
CI
2021Seagen Swings to Q3 Loss as Revenue Drops; Shares Rise After Hours
MT
2021Seagen Inc. Enters into License Agreement with RemeGen Co., Ltd
CI
2021China's biotech sector comes of age with big licensing deals, global ambitions
RE
2021Remegen Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2021
CI
2021REMEGEN : Completes Phase II Trial of Berger's Disease Treatment in China; Shares Jump 3%
MT
2021REMEGEN : Strikes $2.6 Billion Cancer Drug Licensing Deal with Nasdaq-listed Seagen
MT
2021Announces Preliminary Result of Telitacicept in the Phase II Study to Treat IGA Nephrop..
CI
2021REMEGEN : Wins Regulatory Nod to Conduct Clinical Trial of Tumor Drug in Australia
MT
2021RemeGen Co., Ltd. Receives an Ethical Approval from the Human Research Ethics Committee..
CI
2021REMEGEN : China Accepts RemeGen's New Drug Application for Cancer Medication
MT
2021Remegen Co., Ltd. Announces That the National Medical Products Administration Has Accep..
CI
2021REMEGEN : Cancer Drug Secures Breakthrough Therapy Designation in China
MT
2021REMEGEN : Shanghai Bourse Accepts RemeGen's IPO Application
MT
2021REMEGEN CO., LTD.(SEHK : 9995) added to FTSE All-World Index
CI
2021REMEGEN : Drug Granted Marketing Approval
MT
2021REMEGEN : Announcement regarding h share full circulation listing approval granted by the ..
PU
2021REMEGEN : (1) proposed issue of a shares and listing on the sci-tech board and other ancil..
PU
2021REMEGEN : Notice of the 2021 first class meeting of h shareholders
PU
2021REMEGEN : Proxy form for use at the 2021 first class meeting of h shareholders
PU
2021REMEGEN : Proxy form for use at the 2021 first class meeting of domestic shareholders and ..
PU
2021RemeGen Shareholders to Vote June 1 on Shanghai Listing Proposal
MT
2021REMEGEN : Notice of the 2021 first class meeting of domestic shareholders and unlisted for..
PU
2021REMEGEN : Notice of the 2021 second extraordinary general meeting
PU
2021REMEGEN : Proxy form for use at the 2021 second extraordinary general meeting
PU
2021RemeGen Eyes Secondary Listing in Shanghai
MT
2021REMEGEN : Proposed issue of a shares and listing on the sci-tech board and other ancillary..
PU
2021RemeGen Co., Ltd. Announces Board Changes
CI
2021Certain Domestic Shares of RemeGen Co., Ltd. are subject to a Lock-Up Agreement Ending ..
CI
2021REMEGEN : Buys Research and Development Equipment from MabPlex International for Nearly $3..
MT
2021REMEGEN : Connected transaction in relation to acquisition of assets
PU
2021Remegen Co., Ltd. Enters into an Equipment Purchase Contract and A Purchase Contract wi..
CI
2021REMEGEN : Notice of 2020 annual general meeting
PU
2021REMEGEN : Clarification announcement relating to the 2020 results announcement
PU
2021REMEGEN : Closure of register of members for 2020 annual general meeting and 2021 second e..
PU
2021Remegen Co., Ltd. Announces Change of Principal Place of Business in Hong Kong
CI
2021RemeGen Co., Ltd. Announces Earnings Results for the Year Ended December 31, 2020
CI
2021REMEGEN : Inside information announcement - approval by the csrc of the application in res..
PU
2021REMEGEN : Poll results of the 2021 first extraordinary general meeting
PU
2021REMEGEN CO., LTD.(SEHK : 9995) added to S&P Global BMI Index
CI
2021REMEGEN : Wins Conditional Marketing Nod for Lupus Drug in China
MT
2021REMEGEN : Inside information announcement - national medical products administration grant..
PU
2021Remegen Co., Ltd. Announces National Medical Products Administration Granted Conditiona..
CI
2021REMEGEN : Proxy form for use at the 2021 first extraordinary general meeting
PU
2021REMEGEN : Notice of 2021 first extraordinary general meeting
PU
2021REMEGEN : (1) proposed adoption of the first h share award and trust scheme; (2) proposed ..
PU
2020REMEGEN : Shares Surge 13% as Kidney Drug Wins US FDA Nod to Start Phase Two Trial
MT
2020REMEGEN : Raises $74 Million More from Exercising Over-Allotment Option on IPO
MT
2020REMEGEN : Solid Tumor Drug Wins Clinical Trial Approval in China
MT
1  2Next